Group 4 (Non-basal Breast Cancer Cluster): Enriched for luminal and HER2-positive breast cancers, this group points to differences in hormone receptor signaling and distinct oncogenic pathways, aligning with known breast cancer subtypes and their varying treatment responses. This evidence concerns the gene ERBB2 and breast carcinoma.